COMMITMENTS (Details) |
3 Months Ended | |||||
---|---|---|---|---|---|---|
Jan. 31, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Mar. 31, 2023
USD ($)
|
Mar. 08, 2024
USD ($)
site
|
Feb. 01, 2024 |
Mar. 31, 2022
USD ($)
|
|
Long-term Purchase Commitment [Line Items] | ||||||
Operating lease, prior notice for cancellation | 1 month | |||||
Monthly rent expense | $ 1,800 | |||||
Lease commenced, initial period | 3 years | |||||
Rent expense | $ 5,000 | $ 4,000 | ||||
Research and development | 2,428,000 | $ 1,681,000 | ||||
Triple Ring Technologies | ||||||
Long-term Purchase Commitment [Line Items] | ||||||
Purchase commitments | $ 1,700,000 | |||||
Remaining commitment | 300,000 | |||||
Clinical Research Organization | ||||||
Long-term Purchase Commitment [Line Items] | ||||||
Remaining commitment | 700,000 | |||||
Amount to be paid to Clinical Research Organization | $ 500,000 | |||||
Number of planned sites to carrying out the clinical study | site | 5 | |||||
Research and development expense, expected cost | 800,000 | |||||
Research and development | 300,000 | |||||
Remaining commitment accrued | $ 200,000 |
X | ||||||||||
- Definition Accrued Purchase Commitment Liability, Current No definition available.
|
X | ||||||||||
- Definition Lessee, Operating Lease, Monthly Rent Expense No definition available.
|
X | ||||||||||
- Definition Lessee, Operating Lease, Prior Notice For Cancellation No definition available.
|
X | ||||||||||
- Definition Research And Development Expense, Expected Cost No definition available.
|
X | ||||||||||
- Definition Research And Development, Number Of Clinical Study Sites No definition available.
|
X | ||||||||||
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. No definition available.
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|